Latest News

Careful selection of pharmacotherapy and close monitoring are crucial to ensuring safety and efficacy.

The indication is for the treatment adult and pediatric patients who weight at least 30 kg.

Pharmacists are key to closing care gaps and supporting long-term recovery.

Guselkumab becomes the first and only IL-23 inhibitor with a fully subcutaneous induction regimen for adults with ulcerative colitis.

Idecabtagene vicleucel shows a lower infection risk than other BCMA therapies for multiple myeloma.

Linvoseltamab combined with carfilzomib shows promising results in treating relapsed refractory multiple myeloma.

The approval is supported by findings from the MK-3475A-D77 study.

The Advisory Committee on Immunization Practices (ACIP) voted to recommend that COVID-19 vaccines be administered through individual-based decision-making.

Iberdomide enhances chimeric antigen receptor (CAR) T-cell therapy effectiveness in multiple myeloma, boosting immune response and cell functionality.

Discover effective strategies for managing eczema, dry skin, sun protection, and acne with expert recommendations for over-the-counter treatments.

A multicenter registry analysis reveals that high-risk cardiovascular patients often miss opportunities to receive pneumococcal and influenza vaccinations, showcasing gaps that could be filled by pharmacists.

Intravenous immunoglobulin (IVIG) treatment significantly reduces infection rates in multiple myeloma patients receiving BCMA bispecific antibodies, showcasing its clinical benefits.

The BMJ study highlights that young children vaccinated against influenza in October experience the greatest protection, with lower infection rates than those vaccinated earlier.

Members of the Advisory Committee on Immunization Practices (ACIP) voted to restrict the combined measles, mumps, rubella, and varicella (MMRV) vaccine and hepatitis B vaccine for certain age groups.

With this approval, an effective, nonsteroidal treatment option is available for young patients.

Participating in a pharmacist-led secondary intervention clinic helped achieve large reductions in cholesterol levels among patients who have experienced an acute coronary syndrome.

Teclistamab and other bispecific antibodies enhance multiple myeloma treatment but significantly increase infection risks, necessitating proactive management strategies.

Teclistamab shows promising results in newly diagnosed multiple myeloma, enhancing tolerability and achieving high rates of minimal residual disease negativity.

Long-term care pharmacists are significant in lessening the vaccine hesitancy hurdle among facility residents.

Elranatamab combined with daratumumab and lenalidomide shows promising results for treating newly diagnosed multiple myeloma, enhancing patient outcomes.

Pharmacists play a critical role in optimizing triazole therapy in preventing and managing invasive fungal infections.